Business Description
Foghorn Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US3441741077
Share Class Description:
FHTX: Ordinary SharesTotal Employee Number:
106Description
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.37 | |||||
Equity-to-Asset | -0.34 | |||||
Debt-to-Equity | -0.55 | |||||
Debt-to-EBITDA | -0.54 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -3.73 | |||||
Beneish M-Score | -1.89 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 2.1 | |||||
3-Year EBITDA Growth Rate | 23 | |||||
3-Year EPS without NRI Growth Rate | 24.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.64 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 73.52 | |||||
9-Day RSI | 75.17 | |||||
14-Day RSI | 72.53 | |||||
3-1 Month Momentum % | -16.12 | |||||
6-1 Month Momentum % | -25.39 | |||||
12-1 Month Momentum % | -28.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.92 | |||||
Quick Ratio | 2.92 | |||||
Cash Ratio | 2.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10.7 | |||||
Shareholder Yield % | -12.71 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -286.16 | |||||
Net Margin % | -266.88 | |||||
EBITDA Margin % | -276.45 | |||||
FCF Margin % | -309.73 | |||||
OCF Margin % | -309.65 | |||||
ROA % | -33.92 | |||||
ROIC % | -87.65 | |||||
3-Year ROIIC % | -291.16 | |||||
ROC (Joel Greenblatt) % | -297.52 | |||||
ROCE % | -53.71 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 13.42 | |||||
EV-to-EBIT | -2.57 | |||||
EV-to-Forward-EBIT | -2.38 | |||||
EV-to-EBITDA | -2.66 | |||||
EV-to-Revenue | 7.35 | |||||
EV-to-Forward-Revenue | 15.02 | |||||
EV-to-FCF | -2.37 | |||||
Price-to-GF-Value | 1.45 | |||||
Earnings Yield (Greenblatt) % | -38.91 | |||||
FCF Yield % | -25.04 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FHTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Foghorn Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 28.224 | ||
| EPS (TTM) ($) | -1.16 | ||
| Beta | 3.6527 | ||
| 3-Year Sharpe Ratio | 0.28 | ||
| 3-Year Sortino Ratio | 0.56 | ||
| Volatility % | 34.36 | ||
| 14-Day RSI | 72.53 | ||
| 14-Day ATR ($) | 0.389314 | ||
| 20-Day SMA ($) | 4.72175 | ||
| 12-1 Month Momentum % | -28.7 | ||
| 52-Week Range ($) | 3.27 - 6.95 | ||
| Shares Outstanding (Mil) | 58.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Foghorn Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Foghorn Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 116 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 24 days | ||
| General meeting for 2026 | 2026-06-24 09:00 | 4.14 (+0.24%) | ||
| Guidance call for 2026 | 2026-06-09 13:20 | 3.71 (-1.33%) | ||
| TD Cowen 7th Annual Oncology Innovation Summit | 2026-05-26 08:30 | 4.22 (+1.69%) | ||
| Guidance call for 2026 | 2026-05-20 11:00 | 3.60 (-4.26%) | ||
| H.C. Wainwright 4th Annual Bioconnect Investor Conference | 2026-05-19 | 3.82 (+0.26%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 4.68 (-0.64%) | ||
| Annual report for 2025 | 2026-03-11 | 5.49 (+0.73%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-11 | 5.49 (+0.73%) |
Show
Entries
Foghorn Therapeutics Inc Frequently Asked Questions
What is Foghorn Therapeutics Inc(FHTX)'s stock price today?
The current price of FHTX is $5.95. The 52 week high of FHTX is $6.95 and 52 week low is $3.27.
When is next earnings date of Foghorn Therapeutics Inc(FHTX)?
The next earnings date of Foghorn Therapeutics Inc(FHTX) is 2026-08-05 Est..
Does Foghorn Therapeutics Inc(FHTX) pay dividends? If so, how much?
Foghorn Therapeutics Inc(FHTX) does not pay dividend.
Guru Commentaries on NAS:FHTX
No articles.
Press Release
Articles on Foghorn Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers